Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job wor...
Data could not be retrieved
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.3% | ||
| P/E Ratio | 58.7x | ||
| Revenue | 1.551 B | ||
| Net Income to Company | 526.6 M |
| 506879 | Peers | Sector | |
|---|---|---|---|
Market Cap | 30.913 B | 245.4 B | 5.741 B |
Price % of 52 Week High | 72.7% | 77.5% | 61.5% |
Dividend Yield | 0.3% | 0.7% | 0.0% |
Shareholder Yield | 0.2% | 0.7% | -0.6% |
1 Year Price Total Return | 4.2% | 7.7% | -11.5% |
Beta (5 Year) | -0.16 | 0.47 | 0.64 |
No data available
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 1,484 | 1,698 | 1,551 | 389 | 395 |
| Operating Income | 719 | 752 | 687 | 168 | 173 |
| Net Profit | 580 | 592 | 527 | 130 | 130 |
| Diluted EPS | 5.32 | 5.43 | 4.83 | 1.19 | 1.19 |
| EBITDA | 737 | 776 | 715 | 172 | 179 |
| Balance Sheet | |||||
| Cash & ST Invest. | 89 | 146 | 181 | 47 | 181 |
| Current Assets | 617 | 476 | |||
| Total Assets | 1,663 | 2,211 | |||
| Current Liabilities | 153 | 162 | |||
| Total Liabilities | 172 | 197 | |||
| Total Equity | 1,491 | 2,014 | 2,234 | 1,780 | 2,234 |
| Total Debt | 4.19 | 28 | 34 | 23 | 34 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 395 | 642 | |||
| Cash From Investing | (204) | (552) | |||
| Cash From Financing | (133) | (86) | |||
| Free Cash Flow | 158 | (104) | (26) | 0.00 | - |